Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

30 Jul 2008
Tatjana May appointed Chair of Shire’s Corporate Responsibility Committee

Basingstoke, UK and Philadelphia, US – 30 July 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is pleased to announce the appointment of Tatjana May as Chair of the Corporate Responsibility Committee with immediate effect. Tatjana, General Counsel, Company Secretary and Executive Vice President, Global Legal Affairs, has been with Shire since 2001. Shire also announces that it was recently awarded Gold status by Business in the Community for its Corporate Responsibility (CR) commitment, initiatives and actions. Business in the Community's CR Index is the UK’s leading benchmark of responsible business. It helps companies to integrate and improve responsibility throughout their operations by providing a systematic approach to managing, measuring and reporting on business impacts in society and on the environment. The CR Index assesses the extent to which corporate responsibility strategy is integrated into business practice throughout an organisation. It provides a benchmark for companies to evaluate their management practices in four key areas of corporate responsibility (community, environment, marketplace and workplace) and performance in a range of environmental and social impact areas. Shire scored particularly highly in corporate strategy and management practice. As part of Shire’s CR approach, the Company is continually developing its approach to environmental issues and a Global Environmental Impact Analysis team leads and implements specific environmental programs, initiatives and activities with support from functional areas and business units. These include environmental impact assessments, defining and monitoring Shire’s carbon footprint and establishing reduction targets. Shire’s CR progress is reported publicly on its dedicated CR website at http://www.shirecr.com/shirecr/home/and in its Annual Report. Angus Russell, Shire’s Chief Executive, commented: “CR has always been a priority for everyone at Shire and everything we do is underpinned by a strong sense of our responsibilities as a specialty biopharmaceutical company. From detailed business policies to practical day-to-day action, the idea of CR guides and inspires everyone who works at Shire. We’re very pleased with our recent Gold award and I’m delighted with Tatjana May’s appointment as our new Committee Chair.” For further information please contact: Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Jessica Cotrone (North America) +1 617 613 4640 Notes to editors SHIRE LIMITED Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: http://www.shire.com

« Back to Shire news

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device
.